The earnings call highlighted strong clinical adoption and strategic partnerships, but also revealed significant revenue and margin challenges. While the company is confident in its clinical and reimbursement advancements, financial performance faced headwinds due to biopharma volatility and revenue declines.

Company Guidance

In the third quarter of 2025, Personalis reported significant progress in its Win-in-MRD strategy, with clinical test volumes reaching 4,388, marking a 26% sequential and 364% year-over-year growth. The company achieved $14.5 million in revenue, surpassing the high end of its estimates, despite a 44% decrease compared to the previous year due to declines from partners like Natera and VA MVP. Personalis now has over 700 physicians ordering their NeXT Personal test, which boasts the capability of detecting a single fragment of tumor DNA in a million, positioning the company well for a market expected to exceed $20 billion. The guidance for full-year revenue has been adjusted to a range of $68 million to $73 million, reflecting biopharma revenue variability. The company anticipates achieving two Medicare coverage decisions by the end of the year, with ongoing submissions under review by MolDX. Despite these adjustments, Personalis remains focused on clinical adoption and reimbursement efforts, with a strong cash position of $150.5 million to support its strategy.

Significant Clinical Test Growth

Delivered 4,388 clinical tests, marking a 26% sequential and 364% year-over-year growth. More than 700 physicians are now ordering NeXT Personal, demonstrating strong clinical adoption.

Strong Financial Position

Personalis ended the third quarter with $150.5 million in cash and short-term investments, maintaining a strong balance sheet with no significant debt.

Partnership and Collaboration Success

The strategic partnership with Tempus exceeded expectations, achieving the primary volume target for the year ahead of schedule. Signed two major prospective clinical trials with biopharma customers.

Advancements in Reimbursement and Clinical Evidence

Submitted three dossiers for coverage with MolDX and confident in targeting two coverage decisions by the end of the year. Presented promising data from AstraZeneca's Phase III studies highlighting the superiority of NeXT Personal.

Personalis (PSNL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PSNL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	-0.29 / -	-0.23	―	―	―
Nov 04, 2025	2025 (Q3)	-0.27 / -0.24	-0.64	62.50% (+0.40)	―
Aug 05, 2025	2025 (Q2)	-0.24 / -0.23	-0.24	4.17% (<+0.01)	―
May 06, 2025	2025 (Q1)	-0.25 / -0.18	-0.26	30.77% (+0.08)	―
Feb 27, 2025	2024 (Q4)	-0.28 / -0.23	-0.54	57.41% (+0.31)	―
Nov 06, 2024	2024 (Q3)	-0.35 / -0.64	-0.6	-6.67% (-0.04)	―
Aug 07, 2024	2024 (Q2)	-0.37 / -0.24	-0.5	52.00% (+0.26)	―
May 08, 2024	2024 (Q1)	-0.41 / -0.26	-0.61	57.38% (+0.35)	―
Feb 28, 2024	2023 (Q4)	-0.50 / -0.54	-0.67	19.40% (+0.13)	―
Nov 07, 2023	2023 (Q3)	-0.52 / -0.60	-0.58	-3.45% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PSNL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$8.73	$7.66	-12.26%
Aug 05, 2025	$5.64	$4.40	-21.99%
May 06, 2025	$4.00	$4.84	+21.00%
Feb 27, 2025	$4.24	$4.14	-2.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Personalis (PSNL) report earnings?

Personalis (PSNL) is schdueled to report earning on Feb 19, 2026, After Close (Confirmed).

What is Personalis (PSNL) earnings time?

Personalis (PSNL) earnings time is at Feb 19, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PSNL EPS forecast?

PSNL EPS forecast for the fiscal quarter 2025 (Q4) is -0.29.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing